RecruitingPhase 2NCT07080567

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial

Sponsor

Emmanuel Carrera

Enrollment

80 participants

Start Date

Jul 14, 2025

Study Type

INTERVENTIONAL

Conditions

Stroke Ischemic Stroke Stroke, Acute

Summary

MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

Informed consent as documented by signature
≥18 years at time of signing of informed consent
Acute ischemic stroke.
Stroke onset < 7 days from randomization.
Contralateral, unilateral, incomplete upper limb paresis, incl. :
FMA-UE < 63/66
Residual voluntary finger extension (VFE) of > 10 degrees

Exclusion Criteria11

Pregnancy/lactation or positive pregnancy test in women of childbearing age
Pre-stroke handicap (mRS > 2)
Diseases affecting motor function (e.g., Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS))
Participation in another study with investigational medicinal product within 30 days preceding and during the present study
Enrolment of the investigator, his/her family members, employees, or other dependent persons
Known hypersensitivity to Maraviroc, Mannitol, peanuts, or soy
History of significant liver disease, hepatitis, elevated liver function tests (> 1.5 upper limit of normal)
History of significant renal disease or End Stage Renal Disease/dialysis, acute renal injury, Creatinine Clearance (CrCl < 30ml/min/1.73m2)
Patients with cardiovascular comorbidities and risk for orthostatic hypotension
HIV infection
Concomitant use of strong CYP3A4 inhibitors or inducers